Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review

Q Cao, X Wu, Q Zhang, J Gong, Y Chen… - Frontiers in …, 2023 - frontiersin.org
Abnormal cellular apoptosis plays a pivotal role in the pathogenesis of Multiple Myeloma
(MM). Over the years, BCL-2, a crucial anti-apoptotic protein, has garnered significant …

Advancements in programmed cell death research in antitumor therapy: a comprehensive overview

S Wei, C Han, S Mo, H Huang, X Luo - Apoptosis, 2024 - Springer
Cell death is a normal physiological process within cells that involves multiple pathways,
such as normal DNA damage, cell cycle arrest, and programmed cell death (PCD). Cell …

Proteomic alteration in the progression of multiple myeloma: A comprehensive review

NH Ismail, A Mussa, MJ Al-Khreisat, S Mohamed Yusoff… - Diagnostics, 2023 - mdpi.com
Multiple myeloma (MM) is an incurable hematologic malignancy. Most MM patients are
diagnosed at a late stage because the early symptoms of the disease can be uncertain and …

Advances in the management of myeloma: an update

T Meenaghan, A Hayat, G Walpole… - British Journal of …, 2023 - magonlinelibrary.com
Myeloma is an aggressive B-cell malignancy resulting from an uncontrolled production of
plasma cells in the bone marrow. A multitude of drugs and combinations of drugs are now …

Non-producer multiple myeloma presenting with acute hyperammonemic encephalopathy: case report

K Verma, T Zhang, D Mueller, J Li, V Sanchorawala… - Diagnostic …, 2023 - Springer
Background Hyperammonemic encephalopathy (HE) is a rare and life-threatening
complication of multiple myeloma, with underlying mechanisms that are not fully understood …

[HTML][HTML] Multiple Myeloma in the Era of Novel Agents and Stem Cell Therapies

KA Al-Anazi - Recent Updates on Multiple Myeloma, 2023 - intechopen.com
The recent availability of several lines of novel therapeutic agents such as
immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies; the …

[HTML][HTML] OGT's insights from ASH 2023: Part 2–Old biomarkers, new tricks

OGT All - Technology, 2024 - ogt.com
In the 23 years since the first approval of a targeted therapy (Gleevec) 1 in chronic myeloid
leukemia, the implementation of precision medicine across hematological malignancies has …

[引用][C] 复发/难治性多发性骨髓瘤治疗药物的研究进展

潘俊杰, 潘杰, 王乐 - 中国当代医药, 2024